Please read online the lastest updated versions http://www.cdc.gov/vhf/ebola/qa.html
The Journal of Infectious Diseases, jiy435, https://doi.org/10.1093/infdis/jiy435.
Many outbreaks reported high proportions of infected HWs. Similar HW infection rates and exposure risk factors in both past and recent EVD and MVD outbreaks emphasize the need to improve the implementation of approp...riate infection control measures consistently across all healthcare settings.
more
In 2016 CRS leveraged the robust infrastructure of its large, multi-sectoral orphans and vulnerable children (OVC) program in Nigeria by expanding the program's core mandate to include community childhood TB casefinding, with a focus on highly vulnerable children and their caregivers
NATIONAL TUBERCULOSIS AND LEPROSY PROGRAMME
A Guide for low income countries
PERC produces regional and member state situation analyses, updated regularly.
Breastfeeding is the cornerstone of infant and young child survival, nutrition and development and maternal health. The World Health Organization recommends exclusive breastfeeding for the first 6 months of life, followed by continued breastfeeding with appropriate complementary foods for up to 2 ye...ars and beyond.1 Early and uninterrupted skin-toskin contact, rooming-in2 and kangaroo mother care3 also significantly improve neonatal survival and reduce morbidity and are recommended by WHO.
Corrigendum 23 June 2020
more
Rev Panam Salud Publica 45, 2021 |
The major neglected tropical diseases, Taenia solium taeniosis/cysticercosis and schistosomiasis caused by Schistosoma mansoni or S. haematobium are presumed to be widely distributed in Africa. Taenia solium taeniosis/ cysticercosis has been reported as an emerging disease in different regions of Af...rica [1, 2], but currently the exact distribution remains unclear. Reported prevalences of T. solium taeniosis and cysticercosis in African countries are not extensive and are further complicated by the lack of ‘gold standard’ tests for diagnosis.
more
COVID-19 has altered health sector capacity in low-income and middle-income countries (LMICs). Cost data to inform evidence-based priority setting are urgently needed. Consequently, in this paper, we calculate the full economic health sector costs of COVID-19 clinical management in 79 LMICs under di...fferent epidemiological scenarios.
more
A person who lives in or has traveled in the previous 14 days to areas with dengue transmission, and presents with acute fever that has typically lasted 2 to 7 days, and two or more of the following clinical manifestations: nausea or vomiting, exanthema, headache or retro-orbital pain, myalgia or ar...thralgia, petechiae or positive tourniquet test (+), leukopenia, with or without any warning sign or sign of severity. A suspected case is also considered to be any child who resides in or has traveled in the previous 14 days to an area with dengue transmission that presents acute febrile symptoms, usually for 2 to 7 days, without an apparent focus.
more
In April 2020, Gavi and COVAX joined the Access to COVID-19 Tools Accelerator (ACT-A) to provide equitable global access to COVID-19 vaccines to tackle the pandemic. In June 2020, the Gavi COVAX Advance Market Commitment (AMC) was launched to finance equitable access in 92 lower-income countries. Si...nce then, US$ 10 billion has been raised for the AMC to procure vaccines and support delivery. Despite a challenging supply situation, COVAX has now shipped one billion doses to 144 countries, including over 870 million to AMC economies.
more
This threat assessment addresses the implications of the ongoing Marburg virus disease (MVD) outbreak in
Rwanda for the European Union/European Economic Area (EU/EEA). MVD is a severe disease in humans and,
although uncommon, it has the potential to cause epidemics with significant case fatality. ...All recorded MVD
outbreaks to date have originated in Africa. MVD is not an airborne disease and is considered not to be
contagious before symptoms appear. Direct contact with the blood and other body fluids of infected people
and animals or indirect contact with contaminated surfaces and materials like clothing, bedding and medical
equipment is required for transmission. The risk of infection is minimised when proper infection prevention and
control precautions are strictly followed. There is no approved treatment or vaccine for MVD; however, several
pharmaceuticals and candidate MVD vaccines are under investigation.
more